The Impact of Pre-Sedation Conferences on Treatment-Resistant Distress in Cancer Patients

A Study of the Impact of Pre-Sedation Conferences and Subsequent Drug Selection on Life Outcomes for Treatment-Resistant Distress in Cancer Patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1050230148

Enrollment

250

Registered

2023-12-21

Start date

2023-09-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignancy

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Cancer patients and families with pre-sedation conferences between December 1, 2020 and December 31, 2025

Exclusion criteria

Exclusion criteria: Pediatric (under 18 years old) cancer patients and their families

Design outcomes

Primary

Measure	Time frame
Primary composite endpoints (1) Factors affecting the number of days from the start of sedation to death (2) Patient/family satisfaction after administration of drugs for symptom relief (3) Evaluation by medical staff after administration of drugs for symptom relief	—

Secondary

Measure	Time frame
Prediction of prognosis at the start of sedation and number of days from the start of sedation to death; names of drugs used for sedation and dosage (starting dose, maintenance dose, maximum dose); number of days from conference to death and drugs and dosage used (starting dose, maintenance dose, maximum dose) for cases in which symptoms were relieved with medical narcotics or other drugs without sedatives; comparison of major distress symptoms in cases in which symptom relief was possible without sedatives and those in which sedatives were necessary.	—

Measure

Time frame

Prediction of prognosis at the start of sedation and number of days from the start of sedation to death; names of drugs used for sedation and dosage (starting dose, maintenance dose, maximum dose); number of days from conference to death and drugs and dosage used (starting dose, maintenance dose, maximum dose) for cases in which symptoms were relieved with medical narcotics or other drugs without sedatives; comparison of major distress symptoms in cases in which symptom relief was possible without sedatives and those in which sedatives were necessary.

—

Contacts

Public ContactTakae Inui

Hyogo Mrdical University Hospital

tinui@hyo-med.ac.jp+81-798-45-6819

Outcome results